Corcept Therapeutics (CORT) Reports Significant Survival Improvement in Ovarian Cancer Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: stocktwits
- Significant Survival Improvement: In the ROSELLA trial, patients receiving relacorilant combined with nab-paclitaxel had a median overall survival of 16 months compared to 11.9 months for those on nab-paclitaxel alone, indicating a substantial survival benefit that may offer new hope for ovarian cancer patients.
- Reduced Risk of Disease Progression: Earlier data showed a roughly 30% reduction in the risk of disease progression for those treated with the combination, which not only enhances treatment efficacy but also has the potential to redefine clinical treatment standards and improve patient quality of life.
- Good Safety Profile: The safety findings for the combination therapy align with established profiles, with no new adverse events reported, suggesting that the drug can provide meaningful clinical benefits without adding extra risk, thus enhancing its feasibility for clinical use.
- Positive Market Reaction: Following the trial results, Corcept's stock surged over 14% in morning trading on Thursday, with investor sentiment shifting from 'bearish' to 'bullish', reflecting strong confidence in the drug's future potential.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 91.00 USD with a low forecast of 50.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 45.850
Low
50.00
Averages
91.00
High
121.00
Current: 45.850
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DJS Law Group Investigates Corcept for Securities Violations
- Investigation Launched: DJS Law Group is investigating Corcept Therapeutics for potential violations of securities laws, particularly focusing on whether misleading statements were made or important information was withheld from investors, which could undermine investor confidence.
- FDA Response: On December 31, 2026, Corcept revealed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that while the GRACE trial met its primary endpoint, the FDA requires additional evidence of effectiveness, highlighting regulatory hurdles.
- Stock Price Plunge: Following the FDA's announcement, Corcept's shares fell by over 50%, reflecting a pessimistic market sentiment regarding the company's future prospects, potentially leading to significant losses for investors.
- Legal Support: DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through aggressive legal advocacy, demonstrating its commitment to protecting client interests.
Continue Reading
Silver Surges Past $100/oz, Up 230% Yearly
- Silver Price Surge: Silver prices surged past $100 per ounce in New York trading, marking a staggering 230% increase over the past year, indicating a robust recovery in the precious metals market that may attract more investor interest.
- Gold Nears New Highs: Gold prices approached $5,000 per ounce, down nearly 80 percentage points from a year ago, reflecting market concerns over inflation and economic uncertainty, which could drive increased demand for safe-haven assets.
- Strong Performance in Platinum and Palladium: Platinum prices rose 5%, breaking above $2,700 per ounce for the first time, while palladium jumped 6% to exceed $2,000 per ounce, indicating a rebound in automotive demand for these metals that may boost related companies' profitability.
- Rising Energy Prices: Henry Hub natural gas prices increased by 2% to $5.15 per million British thermal units, with a week-to-date gain exceeding 60%, marking the strongest weekly surge on record, reflecting the impact of extreme cold waves on energy demand, which could enhance profits for energy companies.
Continue Reading